AU2008306625B2 - Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use - Google Patents
Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use Download PDFInfo
- Publication number
- AU2008306625B2 AU2008306625B2 AU2008306625A AU2008306625A AU2008306625B2 AU 2008306625 B2 AU2008306625 B2 AU 2008306625B2 AU 2008306625 A AU2008306625 A AU 2008306625A AU 2008306625 A AU2008306625 A AU 2008306625A AU 2008306625 B2 AU2008306625 B2 AU 2008306625B2
- Authority
- AU
- Australia
- Prior art keywords
- independently
- present
- synthesis
- compound according
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97770007P | 2007-10-05 | 2007-10-05 | |
| US60/977,700 | 2007-10-05 | ||
| GB0719644.7 | 2007-10-05 | ||
| GBGB0719644.7A GB0719644D0 (en) | 2007-10-05 | 2007-10-05 | Therapeutic compounds and their use |
| PCT/GB2008/003362 WO2009044162A1 (en) | 2007-10-05 | 2008-10-06 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008306625A1 AU2008306625A1 (en) | 2009-04-09 |
| AU2008306625B2 true AU2008306625B2 (en) | 2014-10-16 |
Family
ID=38739312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008306625A Active AU2008306625B2 (en) | 2007-10-05 | 2008-10-06 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8058045B2 (enExample) |
| EP (1) | EP2197874B1 (enExample) |
| JP (1) | JP5511668B2 (enExample) |
| AU (1) | AU2008306625B2 (enExample) |
| CA (1) | CA2738980C (enExample) |
| DK (1) | DK2197874T3 (enExample) |
| ES (1) | ES2604947T3 (enExample) |
| GB (1) | GB0719644D0 (enExample) |
| WO (1) | WO2009044162A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2032701T3 (da) | 2006-06-23 | 2014-02-10 | Alethia Biotherapeutics Inc | Polynukleotider og polypeptider, der er inddraget i cancer |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) * | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP5781932B2 (ja) | 2008-11-03 | 2015-09-24 | アレシア・バイオセラピューティクス・インコーポレーテッド | 腫瘍抗原の生物活性を特異的にブロックする抗体 |
| JPWO2010058846A1 (ja) | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | ４，６−ジアミノニコチンアミド化合物 |
| AR076024A1 (es) * | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| KR101663637B1 (ko) * | 2009-11-13 | 2016-10-07 | 제노스코 | 키나아제 억제제 |
| WO2011085389A1 (en) * | 2010-01-11 | 2011-07-14 | Astraea Therapeutics, Llc | Nicotinic acetylcholine receptor modulators |
| EP2691421B1 (en) | 2011-03-31 | 2016-11-09 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
| KR101880966B1 (ko) * | 2011-06-10 | 2018-07-23 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| WO2013052393A1 (en) * | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| ES2709003T3 (es) | 2011-11-09 | 2019-04-12 | Cancer Research Tech Ltd | Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico |
| EA201992513A1 (ru) | 2012-01-09 | 2020-05-31 | Адс Терапьютикс Са | Способ лечения рака груди |
| JP6096219B2 (ja) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物 |
| WO2013106614A1 (en) * | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| ES2686500T3 (es) * | 2012-01-13 | 2018-10-18 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas |
| SG11201407238VA (en) * | 2012-05-15 | 2014-12-30 | Cancer Rec Tech Ltd | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
| EP2922840B1 (en) | 2012-11-08 | 2016-12-21 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| TWI620737B (zh) | 2012-11-08 | 2018-04-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| US9657009B2 (en) | 2012-11-08 | 2017-05-23 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| JP2017001954A (ja) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
| TWI825663B (zh) * | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| JP7569688B2 (ja) | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN110872277B (zh) * | 2019-11-14 | 2021-06-04 | 浙江大学 | N-取代芳环-2-氨基嘧啶类化合物及用途 |
| CN110684083B (zh) * | 2019-12-06 | 2020-05-15 | 北京诺赛启研再生医学研究院有限公司 | 抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用 |
| EP4298095A4 (en) * | 2021-01-30 | 2025-08-27 | Sperogenix Therapeutics Ltd | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS AND THEIR USES |
| TW202317106A (zh) | 2021-08-27 | 2023-05-01 | 南韓商柳韓洋行 | 作為egfr抑制劑之取代胺基吡啶化合物 |
| TW202317105A (zh) | 2021-08-27 | 2023-05-01 | 南韓商柳韓洋行 | 作為egfr抑制劑之含六員雜芳基之胺基吡啶化合物 |
| CN117777048B (zh) * | 2023-09-25 | 2024-09-20 | 上海科利生物医药有限公司 | 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003093297A2 (en) * | 2002-05-03 | 2003-11-13 | Exelixis, Inc. | Protein kinase modulators and methods of use |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US805369A (en) * | 1904-10-14 | 1905-11-21 | David Marshall | Tomato-peeling machine. |
| US807554A (en) * | 1905-05-25 | 1905-12-19 | Francis S Heffernan | Non-refillable bottle. |
| US3032984A (en) * | 1959-05-12 | 1962-05-08 | United Aircraft Corp | Rocket pump starting system |
| US3101444A (en) * | 1959-06-30 | 1963-08-20 | John R Montgomery | Electronic pressure measuring means for internal combustion engines responsive to pressure caused spark gap resistance change |
| US3035065A (en) * | 1959-11-05 | 1962-05-15 | Union Carbide Corp | Isomaleimides and a process for the preparation thereof |
| US3093297A (en) * | 1961-09-25 | 1963-06-11 | New York Air Brake Co | Hydrostatic transmission |
| US5037285A (en) * | 1983-04-13 | 1991-08-06 | American National Can Company | Apparatus for injection molding and injection blow molding multi-layer articles |
| US5011597A (en) * | 1988-10-11 | 1991-04-30 | Canzoneri Anthony S | Single cell vertical static flow flotation unit |
| US5034869A (en) * | 1989-11-28 | 1991-07-23 | Choi Young J | Device for fixing a ceiling lamp to a ceiling |
| US5121126A (en) * | 1991-03-12 | 1992-06-09 | Bell Atlantic Network Services Inc. | Beacon enhanced telecommunications system and method |
| US6039718A (en) * | 1998-01-20 | 2000-03-21 | Bracco Research Usa | Multiple use universal connector |
| JP3809786B2 (ja) * | 2001-10-01 | 2006-08-16 | ソニー株式会社 | カートリッジ |
| JP4637481B2 (ja) | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Ｃｄｓ１／ｃｈｋ２阻害剤および癌治療における化学療法または放射線療法の補助剤としての２−フェニルベンズイミダゾールおよびイミダゾ−［４，５］−ピリジン |
| BR0213562A (pt) | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| US7202244B2 (en) | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| GB0215775D0 (en) * | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
| GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| AU2004260689B8 (en) | 2003-07-29 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005035541A1 (en) * | 2003-10-07 | 2005-04-21 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
| MXPA06003996A (es) | 2003-10-08 | 2006-07-05 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina cinasa. |
| WO2005037285A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| EP1742935B1 (en) | 2004-04-13 | 2010-02-24 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| DE602006008945D1 (de) | 2005-06-28 | 2009-10-15 | Sanofi Aventis | Isochinolinderivate als inhibitoren von rho-kinase |
| WO2008077554A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
| CN103588704B (zh) * | 2007-03-16 | 2016-09-14 | 斯克里普斯研究学院 | 粘着斑激酶抑制剂 |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
-
2007
- 2007-10-05 GB GBGB0719644.7A patent/GB0719644D0/en not_active Ceased
-
2008
- 2008-10-06 AU AU2008306625A patent/AU2008306625B2/en active Active
- 2008-10-06 DK DK08806506.5T patent/DK2197874T3/en active
- 2008-10-06 ES ES08806506.5T patent/ES2604947T3/es active Active
- 2008-10-06 WO PCT/GB2008/003362 patent/WO2009044162A1/en not_active Ceased
- 2008-10-06 US US12/680,891 patent/US8058045B2/en active Active
- 2008-10-06 CA CA2738980A patent/CA2738980C/en active Active
- 2008-10-06 JP JP2010527532A patent/JP5511668B2/ja active Active
- 2008-10-06 EP EP08806506.5A patent/EP2197874B1/en active Active
-
2011
- 2011-09-23 US US13/241,887 patent/US8367658B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003093297A2 (en) * | 2002-05-03 | 2003-11-13 | Exelixis, Inc. | Protein kinase modulators and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| US8367658B2 (en) | 2013-02-05 |
| ES2604947T3 (es) | 2017-03-10 |
| US20100311730A1 (en) | 2010-12-09 |
| JP5511668B2 (ja) | 2014-06-04 |
| AU2008306625A1 (en) | 2009-04-09 |
| JP2010540610A (ja) | 2010-12-24 |
| CA2738980C (en) | 2015-12-01 |
| US8058045B2 (en) | 2011-11-15 |
| CA2738980A1 (en) | 2009-04-09 |
| EP2197874B1 (en) | 2016-08-31 |
| GB0719644D0 (en) | 2007-11-14 |
| US20120040967A1 (en) | 2012-02-16 |
| EP2197874A1 (en) | 2010-06-23 |
| WO2009044162A1 (en) | 2009-04-09 |
| DK2197874T3 (en) | 2016-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008306625B2 (en) | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | |
| EP2288601B1 (en) | Bicyclylaryl-aryl-amine compounds and their use | |
| EP2822656B1 (en) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | |
| AU2010210019C1 (en) | Compounds and compositions as protein kinase inhibitors | |
| CA2939786C (en) | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use | |
| EP2170886A1 (en) | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors | |
| EP3012249A1 (en) | Compounds and composition as protein kinase inhibitors | |
| WO2024118966A1 (en) | Glutarimide-containing pan-kras-mutant degrader compounds and uses thereof | |
| WO2008075007A1 (en) | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents | |
| AU2021314416B2 (en) | Compound having kinase inhibitory activity | |
| AU2019331328B2 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| CA2906257A1 (en) | Macrocyclic rip2 kinase inhibitors | |
| CA3219002A1 (en) | Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use | |
| EP4209485A1 (en) | Compound having antitumor activity and use thereof | |
| HK1150832A (en) | Compounds and composition as protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |